Clinical manufacturing of CAR T cells: foundation of a promising therapy
The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing of high-quality, clinical-grade CAR-T cell products is a prerequisite for the wide application of this t...
Main Authors: | Xiuyan Wang, Isabelle Rivière |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Oncolytics |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770516300390 |
Similar Items
-
Genetic Engineering and Manufacturing of Hematopoietic Stem Cells
by: Xiuyan Wang, et al.
Published: (2017-06-01) -
Global Manufacturing of CAR T Cell Therapy
by: Bruce L. Levine, et al.
Published: (2017-03-01) -
The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology
by: Yasmin R. Mohseni, et al.
Published: (2020-07-01) -
CAR-NK cells: A promising cellular immunotherapy for cancer
by: Guozhu Xie, et al.
Published: (2020-09-01) -
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
by: Seshu Tyagarajan, et al.
Published: (2020-03-01)